Clinical trial
Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes
NCT00389415 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00389415 |
|---|---|
| Title | Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes |
| Official title | A Multicenter, Open, Long Term Safety Study of 52 Weeks Treatment With Vildagliptin (100 mg qd) In Patients With Type 2 Diabetes (Extension Study of Study CLAF237A1303) |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Vildagliptin |
| Enrollment | 150 |
| Start date | Oct 1, 2006 |
| First posted | Oct 18, 2006 |
| Last update posted | Nov 27, 2008 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: